Zambia Malaria Vaccine Rollout for Children
- Zambia has taken a important step in its fight against malaria by adding the R21/Matrix-M malaria vaccine to its Expanded Programme on Immunization.
- The initial phase of the program will vaccinate over 500,000 children aged six to eight months across 83 districts.
- "We are proud to be one of the countries rolling out the malaria vaccine nationwide. This vaccine gives us new hope as it is a powerful tool to...
“`html
Zambia Launches Nationwide Malaria Vaccination program with R21/Matrix-M vaccine
Table of Contents
What Happened: Zambia’s New Malaria Vaccine Initiative
Zambia has taken a important step in its fight against malaria by adding the R21/Matrix-M malaria vaccine to its Expanded Programme on Immunization. This initiative, announced by UNICEF on tuesday, marks a nationwide effort to combat one of the country’s leading causes of child mortality.
The initial phase of the program will vaccinate over 500,000 children aged six to eight months across 83 districts. These districts have been prioritized based on malaria burden, with 79 identified as having a high burden and four with a moderate burden. An additional five districts will be included in a second rollout phase scheduled for 2026.
“We are proud to be one of the countries rolling out the malaria vaccine nationwide. This vaccine gives us new hope as it is a powerful tool to protect our children and move closer to a malaria-free Zambia,” stated Health Minister Elijah muchima.
The program is a collaborative effort involving the Zambian government, the world Health Institution (WHO), UNICEF, Gavi, the Vaccine Alliance, and other technical and financial partners.
Understanding Malaria in Zambia: Disease Burden and National Goals
Malaria remains a significant public health challenge in Zambia, classified as endemic and contributing substantially to illness and death, particularly among children under five years of age.
Recent data from 2023 reveals a concerning malaria incidence rate of 523 cases per 1,000 children under five. This highlights the urgent need for effective preventative measures.
The Zambian government’s 2022-2026 National Malaria Elimination Strategic Plan outlines ambitious goals to reduce the impact of malaria. The introduction of the R21/Matrix-M vaccine is a key component of this plan, supporting the overarching goal to cut malaria deaths and incidence by 2026.
The R21/Matrix-M Vaccine: How it Works
The R21/Matrix-M vaccine is a promising new malaria vaccine developed by the University of Oxford and manufactured by the Serum Institute of India. It has demonstrated high efficacy in clinical trials, offering significant protection against malaria in young children. The vaccine works by stimulating the immune system to produce antibodies against the malaria parasite, preventing infection or reducing the severity of illness.
Who is Affected by Malaria in Zambia?
While malaria affects all age groups,children under five are disproportionately vulnerable. Their immune systems are still developing, making them less able to fight off the parasite. Pregnant women are also at increased risk, as malaria can lead to complications during pregnancy,